- Motley Fool•yesterday
Alnylam Pharmaceuticals rebounded in a big way last month.
- Investopedia•2 days ago
Alnylam's hemophilia drug fitusiran was shown safe and effective in mid-stage clinical trials.
- Business Wire•3 days agoAlnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component 5 for the treatment of complement-mediated diseases, in a poster presentation at the 58th Annual Meeting of the American Society of Hematology , held ...
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||40.75 x 100|
|Ask||40.78 x 100|
|Day's Range||39.28 - 40.92|
|52 Week Range||31.38 - 101.30|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-8.99|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|